Source: Annual Congress 2010 - Rare diffuse lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. D. Bakan, D. Kanmaz, G. Camsari, A. Bahadir, G. Özgül, N. Isik, G. Özkan, E. Tuncay, E. Cetinkaya, E. Caglar, A. Gür, S. Altin (Istanbul, Turkey). Clinical course and outcome of pulmonary Langerhans‘-cell histiocytosis. Eur Respir J 2010; 36: Suppl. 54, 748

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary Langerhans‘-cell histiocytosis – clinical futures and outcome Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019 Pulmonary Langerhans histiocytosis: clinical, radiological and functional pattern in spontaneous remission Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 Clinical study of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Clinical and pathological features of 13 adult patients with pulmonary Langerhans‘ cell histiocytosis Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 Clinical characteristics and prognosis of chronic pulmonary aspergillosis Source: International Congress 2019 – Clinical challenges in respiratory infection Year: 2019 Pathological findings in histiocytosis X with pulmonary hypertension Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV Year: 2012 Clinical characteristics of surgically-diagnosed pulmonary cryptococcosis Source: Annual Congress 2011 - Infection in the immunocompromised host: infrequent aetiologies Year: 2011 Incidence, clinical manifestations and prognosis of cardiac sarcoidosis in patients with pulmonary sarcoidosis Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 Clinical presentation and outcome of fibrosing mediastinitis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Langerhans’ cell granulomatosis: clinical manifestations and prognosis of pulmonary lesions Source: Eur Respir J 2004; 24: Suppl. 48, 49s Year: 2004 Pulmonary Langerhans‘ cell histiocytosis (PLCH). Report of two cases diagnosed with pulmonary vascular involvement via exercise tests Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Smoking status and long term clinical outcome in patients with pulmonary Langerhans cell histiocytosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Effectiveness of chemotherapy treatment for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Follow-up of aggressive course pulmonary lymphangioleiomyomatosis Source: Eur Respir J 2005; 26: Suppl. 49, 31s Year: 2005 Cladribine improves lung cysts and pulmonary function in a child with histiocytosis Source: Eur Respir J 2015; 45: 831-833 Year: 2015 Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan Source: Eur Respir J 2010; 36: 202-204 Year: 2010 Special features in progress of cases with pulmonary histiocytosis X Source: Eur Respir J 2002; 20: Suppl. 38, 59s Year: 2002 Pulmonary hypertension in pulmonary Langerhans’ cell histiocytosis Source: Eur Respir Mon 2012; 57: 161-165 Year: 2012 Effectiveness of various therapy regimens for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019